Phio Pharma Receives Positive SMC Recommendation for Phase 1b Study of PH-762

May 28, 2024 — Marlborough, Massachusetts – Phio Pharmaceuticals (NASDAQ: PHIO), a clinical-stage biotechnology firm specializing in gene silencing technology, has announced positive safety results for its lead compound, PH-762, from the first dose cohort of its Phase 1b clinical trial. The company's proprietary INTASYL™ siRNA technology aims to enhance the effectiveness of immune cells in targeting and eliminating tumor cells.

A Safety Monitoring Committee (SMC) recently reviewed the safety data from patients treated with intratumoral PH-762 and found no dose-limiting toxicities or significant adverse events. Based on these promising results, the SMC has recommended proceeding with the escalation to the next dose concentration.

The ongoing Phase 1b clinical trial (NCT 06014086) is designed to assess the safety and tolerability of PH-762 when used as a neoadjuvant therapy. The study involves patients with Stage 1, 2, and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma, and Stage 4 Merkel cell carcinoma. So far, the intratumoral injections have been well-received, showing encouraging safety profiles.

Mary Spellman, MD, acting Chief Medical Officer at Phio Pharmaceuticals, expressed optimism about the future of PH-762, stating, "Safety and efficacy data from our clinical trial will establish the roadmap for continued development of PH-762. We are pleased with the ongoing interest in this potential therapy and look forward to continued enrollment in the clinical study."

Phio Pharmaceuticals Corp. is committed to advancing its INTASYL™ siRNA technology, which is the only self-delivering RNAi platform focused on immuno-oncology therapeutics. INTASYL drugs specifically target proteins that hamper the body's ability to combat cancer, eliminating the need for complex formulations or delivery systems.

The company remains cautious yet optimistic, acknowledging that forward-looking statements carry inherent risks. Factors such as economic conditions, preclinical and clinical activity results, business strategy execution, product development collaborations, and regulatory filings could significantly impact the outcomes. Phio Pharmaceuticals advises stakeholders to consider these risks and not rely solely on forward-looking statements, as actual results may differ.

The biotechnology firm emphasizes its commitment to updating its stakeholders about ongoing developments while adhering to regulatory requirements.

Phio Pharmaceuticals continues to foster collaborations and advance its product candidates towards regulatory approval, aiming to bring innovative cancer therapies to market. The company's focus remains on leveraging its INTASYL™ technology to create effective treatments that enhance the body's immune response to cancer.

As the Phase 1b trial progresses, Phio Pharmaceuticals looks forward to additional data that will further inform the safety and efficacy profile of PH-762. The company's efforts are rooted in a commitment to improving patient outcomes through cutting-edge biotechnological advancements.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!